Last reviewed · How we verify

NCT02179034

Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1

Completed Phase 1 Last updated 4 May 2020
What this trial tests

Phase 1 trial testing Nicotine in Nicotine Dependence, Other Tobacco Product in 59 participants. Completed in 12 June 2017.

Timeline
23 October 2014
Primary endpoint
18 July 2016
12 June 2017

Quick facts

Lead sponsorYale University
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeother
Enrollment59
Start date23 October 2014
Primary completion18 July 2016
Estimated completion12 June 2017
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

Adults 18 to 20, any sex, with Nicotine Dependence, Other Tobacco Product. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to examine if inhaled doses of menthol that produce low and high cooling effects change the appeal of e-cigarettes containing low and high doses of nicotine in adolescent smokers. The hypothesis is that the combination of nicotine and menthol, when compared with menthol or nicotine alone, will result in greater increase in liking of an e-cigarette and greater reduction in nicotine withdrawal.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Nicotine

Trials testing the same drug.

Other recruiting trials for Nicotine Dependence, Other Tobacco Product

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02179034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing